MA56119A - Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques - Google Patents

Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques

Info

Publication number
MA56119A
MA56119A MA056119A MA56119A MA56119A MA 56119 A MA56119 A MA 56119A MA 056119 A MA056119 A MA 056119A MA 56119 A MA56119 A MA 56119A MA 56119 A MA56119 A MA 56119A
Authority
MA
Morocco
Prior art keywords
reagents
reducing
methods
binding drug
serological assays
Prior art date
Application number
MA056119A
Other languages
English (en)
Inventor
Jaume Pons
Sophia Randolph
Bang Janet Sim
Hong Wan
Original Assignee
Alx Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alx Oncology Inc filed Critical Alx Oncology Inc
Publication of MA56119A publication Critical patent/MA56119A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/34—Post-translational modifications [PTMs] in chemical analysis of biological material addition of amino acid(s), e.g. arginylation, (poly-)glutamylation, (poly-)glycylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA056119A 2019-06-07 2020-06-05 Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques MA56119A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858871P 2019-06-07 2019-06-07
US201962934395P 2019-11-12 2019-11-12

Publications (1)

Publication Number Publication Date
MA56119A true MA56119A (fr) 2022-04-13

Family

ID=71899853

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056119A MA56119A (fr) 2019-06-07 2020-06-05 Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques

Country Status (6)

Country Link
US (1) US20200400662A1 (fr)
EP (1) EP3980747A1 (fr)
JP (1) JP7561775B2 (fr)
CN (1) CN114206912B (fr)
MA (1) MA56119A (fr)
WO (1) WO2020247820A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117964732A (zh) 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
CA2999058C (fr) 2016-10-20 2024-03-12 I-Mab Nouveaux anticorps monoclonaux cd47 et leurs utilisations
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
BR112022008817A2 (pt) 2019-11-27 2022-07-26 Alx Oncology Inc Terapias combinadas para tratamento de câncer
KR20230018475A (ko) 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
WO2022078466A1 (fr) * 2020-10-14 2022-04-21 I-Mab Biopharma Co., Ltd. Procédés d'atténuation de l'interférence par des anticorps anti-cd47 thérapeutiques dans des dosages de pré-transfusion
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
CN120202222A (zh) 2022-11-16 2025-06-24 勃林格殷格翰国际有限公司 抗SIRPa抗体的疗效预测性生物标志物
CN116380580A (zh) * 2023-03-15 2023-07-04 中国人民解放军空军军医大学 一种血浆检测前处理方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2111869A1 (fr) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions et procédés pour renforcer le système immunitaire
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
US20140193408A1 (en) 2011-06-16 2014-07-10 Novartis Ag Soluble proteins for use as therapeutics
EP3766511A1 (fr) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University Réactifs sirp-alpha de haute affinité
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
JP6392770B2 (ja) 2012-12-03 2018-09-19 ノビミューン エスアー 抗ｃｄ４７抗体およびその使用方法
HK1216647A1 (zh) 2012-12-12 2016-11-25 Vasculox Inc. 治疗性cd47抗体
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
US9969789B2 (en) 2012-12-17 2018-05-15 Trillium Therapeutics Inc. Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
WO2014123580A1 (fr) 2013-02-06 2014-08-14 Inhibrx Llc Anticorps cd47 n'induisant ni l'appauvrissement en globules rouges ni l'appauvrissement en plaquettes
JP6426693B2 (ja) * 2013-03-15 2018-11-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ｃｄ４７薬の処理上有効量を達成するための方法
WO2016023040A1 (fr) 2014-08-08 2016-02-11 Alexo Therapeutics International Constructions de variant sirp-alpha et leurs utilisations
EP3012271A1 (fr) 2014-10-24 2016-04-27 Effimune Procédé et compositions pour induire la différenciation de cellule suppressives dérivées de myéloïde pour traiter le cancer et les maladies infectieuses
CA2967379A1 (fr) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Anticorps anti-cd47, procedes et utilisations
EA037654B1 (ru) 2014-12-30 2021-04-27 Селджин Корпорейшн Анти-cd47-антитела и их применения
PT3277821T (pt) 2015-03-31 2019-10-31 Novimmune Sa Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos
CN106146670B (zh) 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
WO2016179399A1 (fr) 2015-05-06 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Analogues du cd47 à haute affinité
CN114425077A (zh) 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
CN117964732A (zh) 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
EP3349787A4 (fr) 2015-09-18 2019-03-27 Arch Oncology, Inc. Anticorps cd47 thérapeutiques
AU2016326423A1 (en) 2015-09-21 2018-04-26 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
EP4186927B1 (fr) 2015-10-21 2025-04-23 Ose Immunotherapeutics Procédés et compositions de modification de la polarisation des macrophages en cellules pro-inflammatoires pour traiter le cancer
KR20220163516A (ko) 2016-01-11 2022-12-09 포티 세븐, 인코포레이티드 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
US20190091290A1 (en) 2016-04-15 2019-03-28 Trillium Therapeutics Inc. Macrophage stimulation in cd47 blockade therapy
AR112048A1 (es) 2016-05-09 2019-09-18 Celgene Corp Anticuerpos cd47 y métodos de uso de los mismos
CA3029977A1 (fr) 2016-07-06 2018-01-11 Celgene Corporation Anticorps a faible immunogenicite et leurs utilisations
KR102878970B1 (ko) 2016-08-03 2025-10-30 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CA2999058C (fr) 2016-10-20 2024-03-12 I-Mab Nouveaux anticorps monoclonaux cd47 et leurs utilisations
WO2018075960A1 (fr) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Anticorps cd47 thérapeutiques
CA3042583A1 (fr) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Ameliorations de la therapie de blocage de cd47 par des inhibiteurs de hdac
CA3042581A1 (fr) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Amelioration de la therapie de blocage des cd47 par des inhibiteurs du proteasome
WO2018095428A1 (fr) 2016-11-28 2018-05-31 江苏恒瑞医药股份有限公司 Anticorps cd47, fragment de liaison à l'antigène de l'anticorps cd47 et leur utilisation médicale
JP7173971B2 (ja) 2016-12-09 2022-11-16 アレクトル エルエルシー 抗ＳＩＲＰ－α抗体及びその使用方法
WO2018149938A1 (fr) 2017-02-17 2018-08-23 Ose Immunotherapeutics Nouvelles utilisations d'anticorps anti-sirpg
PT3443010T (pt) 2017-02-17 2024-10-21 Ose Immunotherapeutics Novos anticorpos anti-sirpa e suas aplicações terapêuticas
WO2018175790A1 (fr) 2017-03-22 2018-09-27 Arch Oncology, Inc. Polythérapie pour le traitement de cancers solides et hématologiques
MX2019011624A (es) 2017-03-27 2019-12-05 Celgene Corp Metodos y composiciones para la reduccion de la inmunogenicidad.
CA3057718A1 (fr) 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Therapie par blocage de cd47
MX2019012233A (es) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
HUE067040T2 (hu) 2017-05-16 2024-09-28 Byondis Bv Anti-SIRPalfa antitestek
WO2018236904A1 (fr) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations
EP4368206A3 (fr) 2017-06-21 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Paramètres de dosage pour thérapies ciblant cd47 pour les malignités hématologiques
CN111448210B (zh) 2017-07-26 2024-05-14 四十七公司 抗SIRP-α抗体及相关方法
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途

Also Published As

Publication number Publication date
JP7561775B2 (ja) 2024-10-04
WO2020247820A1 (fr) 2020-12-10
US20200400662A1 (en) 2020-12-24
JP2022535286A (ja) 2022-08-05
EP3980747A1 (fr) 2022-04-13
CN114206912A (zh) 2022-03-18
CN114206912B (zh) 2025-02-11

Similar Documents

Publication Publication Date Title
MA56119A (fr) Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques
EP2438442A4 (fr) Procédés et dosages pour mesurer p95 et/ou p95 dans un échantillon et anticorps spécifiques de p95
EP3665187A4 (fr) Procédés de dosage pour la détection améliorée d'analytes
EP2254568A4 (fr) Procédés et dosages pour détecter et traiter une hypoglycémie
BRPI0819211A2 (pt) Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo
MA53338A (fr) Dosages pour détecter la neurodégénérescence
EP3934684A4 (fr) Apprentissage automatique dans des dosages de cancers fonctionnels
WO2006122311A3 (fr) Puce microfluidique
EP3504347A4 (fr) Procédés de détection de changements de copie génomique dans des échantillons d'adn
PT2274335E (pt) Anticorpos monoclonais capazes de reagirem com diversos subtipos de vírus a da gripe
WO2008048300A3 (fr) Biocapteur de détection pathogène
EP2092355A4 (fr) Ressources de partage dans un système pour éprouver des dispositifs semi-conducteurs
RU2020129667A (ru) Способ детектирования молекулы-мишени и набор для использования в этом способе
ATE466108T1 (de) Optoelektronisches detektionssystem
EP2232264A4 (fr) Réactif d'extraction d'un immunosuppresseur pour dosages immunologiques
EP2344884A4 (fr) Dosage semi-séquentiel pour la détection d'un analyte dans un échantillon
EP3387429A4 (fr) Dispositif doté de procédés intégrés pour la réaction de polymérase en chaîne par transcription inverse (rt-pcr) et/ou d'analyses sur la base de matrice d'adn/protéines
EP2367959A4 (fr) Procédés et réactifs pour raccourcir les temps d'incubation dans des dosages par hybridation
EP1891108A4 (fr) Réactifs et dosages diagnostiques permettant de détecter la protéine psp94
EP3433377A4 (fr) Dosages et procédés pour détecter l'udp-glucose
EP3857226A4 (fr) Procédés et compositions pour éliminer l'interférence de la biotine dans des dosages à l'aide de pièges moléculaires conjugués
EP3469366A4 (fr) Procédé de détection de la présence d'une substance mycobactérienne dans un échantillon au moyen d'au moins deux antigènes
EP4157533A4 (fr) Structures de dosage pour dosages biochimiques en plusieurs étapes
EP3624791A4 (fr) Réactif pour bioconjugaison, sélective vis-à-vis d'un site spécifique, de protéines ou d'anticorps
EP3973253A4 (fr) Procédés de détection de résultats aberrants provoqués par une administration incomplète d'un réactif polyhaptène dans des dosages immunologiques